Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE plus microwave ablation vs conventional TACE plus microwave ablation in advanced primary liver cancer
ChiCTR2100044104Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jul 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pirarubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: median progression-free survival (mPFS). Started Jul 2020; status: recruiting.
02
Drugs
pirarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100044104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044104.